
    
      This is a prospective, open-label, one-arm, single center clinical trial, aimed to evaluate
      the safety, tolerability, and efficacy of Chidamide Combined With Etoposide in Relapsed or
      Refractory NK/T-cell Lymphoma. A total of 30 patients are planned to be enrolled into the
      study. Patients with diagnosis of Relapsed or Refractory NK/T-cell Lymphoma will be treated
      with Chidamide plus Etoposide capsules. The primary end points are objective responder rate
      (ORR) and a time to response(TTR) and response duration (DOR) and progression free
      survival(PFS) and adverse events.
    
  